<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03013634</url>
  </required_header>
  <id_info>
    <org_study_id>TianjinFCH</org_study_id>
    <nct_id>NCT03013634</nct_id>
  </id_info>
  <brief_title>Protective Effects of Dexmedetomidine on Myocardial Injury During Liver Transplantation</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin First Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin First Central Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the protective effect of dexmedetomidine on
      myocardial injury during liver transplantation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Liver transplantation surgery may lead to myocardial injury. Dexmedetomidine, a highly
      specific α2-adrenoeptor agonist, has sedative and analgesic properties without significant
      respiratory depression at the clinically approved dosage. Some investigations indicated that
      dexmedetomidine was able to protect the myocardium via improving the activity of
      Na+-K+-adenosine triphosphate enzyme and Ca2+-adenosine triphosphate, alleviating
      inflammation reaction and avoiding Ca2+ overload. However, the effect and the mechanism of
      dexmedetomidine on myocardial injury during liver transplantation remain unclear.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peri-operative mortality</measure>
    <time_frame>through study completion, an average of 5 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence of cardiac complications</measure>
    <time_frame>from anesthesia induction to 24 hours after operation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evidences of Clinically Definite Myocardial Injury Confirmed by Electrochemiluminescence</measure>
    <time_frame>before skin incision, 0.5 hour min after anhepatic, 2 hours of neohepatic stage,the end of surgery,24 hours after operation</time_frame>
    <description>myohemoglobin,creatine kinase isoenzyme,cardiac troponinⅠ,Heart-type fatty acid-binding protein</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>through study completion, an average of 5 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>length of stay</measure>
    <time_frame>through study completion, an average of 6 weeks</time_frame>
    <description>from date of admission to discharge time</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Evidence of Liver Transplantation</condition>
  <condition>Myocardial Injury</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine infusion:loading 0.5ug/kg for 10min, then 0.5 ug/kg/h until the end of operation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Equal volume normal saline substitute for dexmedetomidine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine infusion:loading 0.5ug/kg for 10min, then 0.5 ug/kg/h until the end of operation.</description>
    <arm_group_label>Dexmedetomidine Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Equal volume normal saline substitute for dexmedetomidine</description>
    <arm_group_label>Normal saline Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  End stage liver disease scheduled for liver transplantation in Tianjin First Center
             Hospital

        Exclusion Criteria:

          -  Pre-existing respiratory failure,renal failure,hepatic encephalopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wenli Yu, PhD</last_name>
    <phone>86-13920098326</phone>
    <email>yzxyuwenli@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>No.24 Fukang Road,Nankai District</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300192</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenli Yu, PhD</last_name>
      <phone>86-13920098326</phone>
      <email>yzxyuwenli@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2016</study_first_submitted>
  <study_first_submitted_qc>January 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2017</study_first_posted>
  <last_update_submitted>January 4, 2017</last_update_submitted>
  <last_update_submitted_qc>January 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tianjin First Central Hospital</investigator_affiliation>
    <investigator_full_name>Wenli Yu</investigator_full_name>
    <investigator_title>Wenli Yu,PhD ,Department of Anesthesiology,Tianjin First Center Hospital</investigator_title>
  </responsible_party>
  <keyword>dexmedetomidine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

